RxDoctor Payments Data

Israel Galtes, MD

Cardiovascular Disease · Homestead, FLNPI 1457326746

Payments from drug & device makers

$330,010in general payments, 2019–2025

Across 628 payments — averaging $525.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$181K
  • Merck$97K
  • Kowa Research Institute, Inc.$43K
  • AstraZeneca$1K
  • Pfizer$1K
  • Johnson & Johnson$995
  • plus $6K from 37 others

What the payments were for

  • Speaking & faculty fees$34,23973%
  • Travel & lodging$1,5903%
  • Food & beverage$11,13724%
  • Education$460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$330,010 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$200,244
Medicare patients
330
Services billed
1,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban486$395,576
XareltoRivaroxaban339$255,292
EntrestoSacubitril/Valsartan278$226,230
MultaqDronedarone Hcl135$146,205
FarxigaDapagliflozin Propanediol188$132,788
Repatha SureclickEvolocumab139$101,022
VerquvoVericiguat78$60,035
Praluent PenAlirocumab75$37,370
NexlizetBempedoic Acid/Ezetimibe73$34,864
BrilintaTicagrelor50$24,347
JardianceEmpagliflozin29$19,805
VascepaIcosapent Ethyl48$19,571
Nifedipine ErNifedipine224$7,979
Clonidine57$7,732
NexletolBempedoic Acid13$7,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,090$395,576486 claims
Johnson & JohnsonXarelto$995$255,292339 claims
NovartisEntresto$180,929$226,230278 claims
AstraZenecaFarxiga, Brilinta, Lokelma$1,244$164,555251 claims
Sanofi-aventis U.S. LLCMultaq$623$146,205135 claims
MerckVerquvo$96,508$60,03578 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$713$42,55686 claims
Boehringer IngelheimJardiance$251$19,80529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Homestead

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →